Form 4: Vaxcyte CFO Andrew Guggenhime Executes Stock Option and Sells Shares

Andrew Guggenhime, President and CFO of Vaxcyte, Inc., exercised stock options and sold shares of common stock on September 18, 2024, according to a Form 4 filing with the SEC.

Summary

• On September 18, 2024, Andrew Guggenhime, the President and CFO of Vaxcyte, Inc., executed a stock option to acquire 8,000 shares of common stock at a price of $5.35 per share.
• Simultaneously, Guggenhime sold a total of 8,000 shares in four separate transactions at weighted average prices ranging from $115.5975 to $117.5311.
• These sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on June 30, 2023.
• Following these transactions, Guggenhime directly owns 90,383 shares of Vaxcyte common stock and holds options for 320,827 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports routine stock transactions by an executive under a pre-existing trading plan. There's no indication of positive or negative implications for the company.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, although the existence of a 10b5-1 plan mitigates this concern.

Industry Context

This filing is a routine disclosure of insider transactions. It's common for executives to exercise stock options and sell shares, especially under pre-arranged trading plans. The impact on Vaxcyte's stock will depend on overall market conditions and company performance.

Comparison to Industry Standards

• Executive compensation packages often include stock options, and it's typical for executives to periodically exercise these options and sell shares for personal financial management.
• The use of a 10b5-1 trading plan is a common practice among public company executives to avoid accusations of insider trading.
• Comparable companies in the biotechnology sector, such as Moderna or BioNTech, also see regular Form 4 filings from their executives.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders if they perceive it negatively, but the 10b5-1 plan mitigates this concern.
• There is no direct impact on employees, customers, suppliers, or creditors.

Key Dates